Tirzepatide — the dual GLP-1/GIP agonist, explained
Tirzepatide (LY3298176) is a synthetic peptide developed by Eli Lilly that simultaneously activates the GLP-1 and GIP receptors. It was the first dual-incretin agonist to reach commercial pharmaceutical status and it represents the generation of incretin pharmacology that sits between semaglutide (GLP-1 mono-agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist). This primer covers the molecule, the dual-agonism mechanism, the SURPASS and SURMOUNT trial programs, dose titration considerations, comparative effect size vs semaglutide, and what researchers should know about working with it.
The molecule. Tirzepatide is a 39-amino-acid synthetic peptide engineered around a modified GIP backbone. Molecular weight is approximately 4813.5 Da. The key structural features: a C20 fatty diacid chain attached via a γ-glutamate linker to Lys20, which provides albumin binding and extends the half-life to approximately 5 days (the basis for once-weekly dosing), and strategic substitutions at positions 2, 13, 19, 20, and 24 that produce the characteristic GLP-1R/GIPR co-binding profile. The peptide is unimolecular — a single chain that engages two different receptors — rather than a conjugate of two separate agonists.
Why dual agonism surprised the field. GIP (glucose-dependent insulinotropic polypeptide) as a mono-agonist had a disappointing clinical history through the 1990s and 2000s. In isolation, GIPR activation produced modest insulin response but little effect on weight or glycemic control sufficient to justify development. The assumption was that GLP-1 was where all the metabolic benefit came from, and GIPR was "along for the ride." Tirzepatide's phase II and phase III data upended this assumption — the dual agonist consistently outperformed matched-dose semaglutide on both HbA1c and weight endpoints, and mechanistic work in mouse knockouts has since suggested that GIPR contributes independently to adipose tissue remodeling and appetite regulation in ways GLP-1R alone does not capture. Whether the GIPR contribution comes from agonism or from receptor desensitization (i.e. functional antagonism) remains debated in the pharmacology literature.
SURPASS trial program — glycemic-regulation research. The foundational efficacy data for tirzepatide in the T2D research cohort comes from the SURPASS-1 through SURPASS-5 phase III trials. The most-cited comparison is Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515 (doi: 10.1056/NEJMoa2107519), the SURPASS-2 head-to-head against semaglutide 1 mg weekly. In that trial, tirzepatide produced HbA1c reductions of 2.01% (5 mg), 2.24% (10 mg), and 2.30% (15 mg) vs 1.86% for semaglutide 1 mg at 40 weeks. Weight-loss differences were more pronounced than glycemic differences. For T2D-context research, the SURPASS-2 paper is the essential starting point.
SURMOUNT trial program — body-composition research. The body-composition research data comes from SURMOUNT-1 through SURMOUNT-5. The headline paper is Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216 (doi: 10.1056/NEJMoa2206038), SURMOUNT-1, a 72-week phase III in adults with obesity without diabetes. Weight reductions at 72 weeks: 15% (5 mg), 19.5% (10 mg), 20.9% (15 mg), vs 3.1% for placebo. The 15 mg arm's ~21% reduction is the number most frequently referenced when comparing tirzepatide to semaglutide (STEP-1 trial published ~15% at 68 weeks for 2.4 mg). For researchers interested in the obesity-context pharmacology, the SURMOUNT-1 paper and its supplementary material (which includes body composition sub-study data) are the primary source.
The discovery and mechanism paper. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14 (doi: 10.1016/j.molmet.2018.09.009) is the Lilly discovery team's account of how tirzepatide was designed and characterized in preclinical models. This is the paper to read for the mechanistic framing and for understanding the specific GLP-1R vs GIPR potency ratio Lilly targeted (and why).
Comparative effect sizes, research-context. At matched weekly doses and matched trial durations, the approximate ordering on weight-related endpoints in phase III data is: semaglutide 2.4 mg produces ~15% body weight reduction at 68 weeks (STEP-1), tirzepatide 15 mg produces ~21% at 72 weeks (SURMOUNT-1), and retatrutide 12 mg produces ~24% at 48 weeks in phase II (Jastreboff 2023). These are trial-level population means with wide individual variance — they should be read as comparative data points for the compound class, not as therapeutic guarantees for any individual subject or experimental arm. All three compounds are in the GLP-1 family and share dose-limiting GI tolerability as the primary practical constraint.
Dose titration in the published literature. Tirzepatide is titrated upward every 4 weeks to manage GI adverse effects. The approved titration schedule starts at 2.5 mg weekly for 4 weeks (not a therapeutic dose — this is the tolerability-building step), then steps to 5, 7.5, 10, 12.5, and 15 mg at 4-week intervals as tolerated. Most research protocols mirror this schedule. Dose-response plateaus above 10 mg in some subgroup analyses, and the 12.5 mg dose is often where practical research protocols settle. The titration is not optional in a research context — skipping steps produces GI symptoms severe enough to compromise subject retention.
Storage, stability, and handling. Tirzepatide in a prefilled pen is stable at 2–8 °C through the labeled expiry date. Once in use (first injection), the pen is typically stable at 2–8 °C for up to 21 days (Lilly's Mounjaro labeling) or longer in research-grade pen formats depending on the stability testing of the specific product. Do not freeze — freeze-thaw cycles degrade the peptide and are grounds for discarding the unit. Protect from light. The pen cartridge is sealed against contamination, which is a meaningful advantage over lyophilized powder + bacteriostatic water workflows common in older peptide research.
What the COA should say. A batch-specific Certificate of Analysis for tirzepatide should include (1) identity confirmation by HPLC-MS against the theoretical mass (~4813.5 Da), (2) purity by reverse-phase HPLC-UV at 214 nm with the main peak integrated and reported as area percent (specification typically ≥ 98.0%, with GMP-grade material releasing at 99.0%+), (3) residual solvent profile per ICH Q3C — acetonitrile, DMF, and TFA are the relevant solvents from the synthesis route, and (4) endotoxin by LAL in EU/mg. For tirzepatide specifically, the C20 fatty diacid modification at Lys20 is a common failure mode in synthesis (incomplete acylation), so the purity chromatogram should be examined for shoulder peaks that could indicate unmodified or partially-modified tirzepatide variants.
When to reach for tirzepatide vs semaglutide vs retatrutide (research framing). In research design, the choice between the three compounds is fundamentally about which receptor arms are being studied. For researchers isolating GLP-1R effects specifically, semaglutide is the cleaner tool because it is the mono-agonist. For researchers studying the additive value of GIPR co-activation, tirzepatide is the essential comparator against semaglutide. For researchers interested in the triple-agonism question (whether adding GCGR adds or subtracts from the GLP-1/GIP stack), retatrutide is the direct experimental tool. Vivaprime stocks all three to support this kind of comparative research protocol.
Research-use only. Vivaprime supplies tirzepatide as research reference material for qualified researchers engaged in in-vitro laboratory work. Although tirzepatide has FDA approval as a therapeutic (Mounjaro for T2D, Zepbound for obesity) through Eli Lilly, the material supplied here is not the FDA-approved pharmaceutical product and is not supplied with the pharmaceutical-grade release documentation required for clinical or patient-facing use. Nothing on this page, including the referenced clinical trial data, constitutes a therapeutic, diagnostic, or consumption recommendation. Purchasers affirm the research-use agreement at checkout.